2023-506977-36-00招募中4 期
Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in adults aged 65 to 79 years in Galicia, Spain
Complexo Hospitalario Universitario De Santiago1 个研究点 分布在 1 个国家目标入组 114,011 人开始时间: 2023年9月13日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 114,011
- 试验地点
- 1
- 主要终点
- The primary endpoint of the study is the occurrence of a hospitalization due to influenza or pneumonia [composite endpoint].
研究概览
简要总结
To evaluate the relative vaccine effectiveness of QIV-HD vs. QIV-SD in reducing the risk of hospitalization for influenza or pneumonia [composite endpoint] in adults aged 65 to 79 years.
入排标准
- 年龄范围
- 65 years 至 65+ years（65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Age 65-79 years residing in the community (only individuals who are not eligible to receive QIV-HD as part of the standard of care).
- •Informed consent form has been signed and dated
排除标准
- •There are no specific exclusion criteria for this study
结局指标
主要结局
The primary endpoint of the study is the occurrence of a hospitalization due to influenza or pneumonia [composite endpoint].
The primary endpoint of the study is the occurrence of a hospitalization due to influenza or pneumonia [composite endpoint].
次要结局
- The secondary endpoints of the study are as follows: 1. Hospitalization for any cardio-respiratory disease [composite endpoint] 2. All-cause hospitalization 3. All-cause mortality 4. Hospitalization for influenza 5. Hospitalization for pneumonia
研究者
Federico Martinon Torres
Scientific
Complexo Hospitalario Universitario De Santiago
研究点 (1)
Loading locations...
相似试验
已完成
4 期
HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in GaliciaInfluenzaNCT06141655Federico Martinón Torres134,476
进行中（未招募）
不适用
Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in BogotáNCT07279298Bogotá District Health Secretariat1,097
进行中（未招募）
4 期
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 YearsNCT07281677Zhejiang Provincial Center for Disease Control and Prevention400
进行中（未招募）
4 期
Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19NCT07279766Tor Biering-Sørensen285,000
进行中（未招募）
1 期
Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older AdultsNCT07295028Sanofi240